Navigation Links
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Date:11/19/2008

atient safety is our top priority, hence we have acted quickly to implement the recommendations of the DMC. Working with our development partner, Takeda, we will continue to evaluate the therapeutic potential of motesanib in non-squamous NSCLC and metastatic breast cancer, as well as in other solid tumors."

"NSCLC continues to be an area where new and effective therapies are needed. We look forward to the follow up recommendations from the DMC in order to chart the best path forward for the development of this molecule," said Nancy Simonian, M.D., chief medical officer, Millennium: The Takeda Oncology Company.

MONET1 (Motesanib NSCLC Efficacy and Tolerability Study) Trial Design

This Phase 3, multicenter, randomized, placebo-controlled, double-blind trial has enrolled 1,100 of 1,240 planned patients with advanced NSCLC. Patients with either squamous or non-squamous NSCLC were allowed in this study. Squamous NSCLC is a histological subtype of NSCLC and accounts for approximately one-third of the study population. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, objective response rate in patients with measurable disease, duration of response and safety. Patients were randomized 1:1 to receive carboplatin and paclitaxel administered every three weeks with or without 125 mg motesanib taken daily.

About Motesanib

Co-developed by Amgen, Takeda Pharmaceutical Company, and Millennium: The Takeda Oncology Company, motesanib is an investigational, highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3). It is also under investigation for its potential direct anti-tumor activity by targeting a family of proteins called tyrosine kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell facto
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
2. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
4. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... , February 27, 2015 Report ... study showing you trends, R&D progress, and predicted revenues ... heading? What are the commercial prospects for this market ... potential revenues and other trends to 2025, discussing data, ... lets you assess regenerative medicine : cell-based therapies ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
(Date:2/27/2015)... February 27, 2015 FACE Skincare~Medical~Wellness, ... has announced a unique combination to take fifteen ... Ultherapy Décolletage is a new treatment introduced that ... procedure specifically indicated to improve lines and wrinkles ... any person who suffers from the stubborn vertical ...
(Date:2/27/2015)... Mediaplanet today announces the launch of its second ... to bring blood health and cancer awareness to the ... this edition go beyond the concept of these insidious ... research and technological strides needed to develop new solutions ... approximately every 3 minutes one person in the ...
(Date:2/27/2015)... Glidewell Laboratories, industry-leading provider of ... its CloudPoint™ family of equipment, software ... monolithic zirconia crowns & bridges, CloudPoint offers dental ... CAD/CAM-produced restorations that doctors demand. Installation of CloudPoint ... can be scanned, managed and produced. After scanning ...
(Date:2/27/2015)... Healthpointe is now performing arthroscopy ... or diseases affecting the elbow , wrist ... throughout Southern California, and are dedicated in providing ... related to the upper extremities. , Dr. ... board-certified and fully trained in treating an array ...
(Date:2/27/2015)... February 27, 2015 Insight Accelerator ... to advance the development of an in-line urine ... solution is being developed in direct response to ... 73% accuracy and error margins with potentially grave ... output measurement and provide trending data analysis to ...
Breaking Medicine News(10 mins):Health News:Face Skincare Announces New Combination Therapy 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 3Health News:Healthpointe is Now Performing Arthroscopic Surgery Techniques for Elbow, Hand and Wrist Injuries and Diseases, such as certain Ganglion Cysts 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3
... ... Schwartzapfel Truhowsky Marcus P.C., offers tips for safer driving on icy highways. , ... New York, NY (PRWEB) January 26, 2010 ... black ice, a New York personal injury attorney says., , ,“Black ice is as dangerous ...
... ... with the opening of a satellite office in Los Angeles and the hiring of additional ... ... , a leading provider of employment background screening, drug testing and physical exam services, today ...
... ... now offering Trek’s Ride+ electric assist bikes to their guests. By being one of the first ... a new world of cycling vacations to a wider range of riders. Now anyone can enjoy ... ...
... ... ... past several years in struggling and integrating the mechanic, electronics, materials, and driving software, the ... be completed during this coming March in 2010. It is not only the mechanic revolution ...
... ... Inc., an industry leader in Continuous Process Improvement (CPI) Training and Certification, ... companies battle tough economic times, they made their On Demand Lean Six ... helped hundreds of organizations to learn the basics of Lean Six Sigma, ...
... ... global concern, and Casual Male Retail Group, Inc. (NASDAQ: CMRG) provides the inspiration to get, ... ... to be a global concern, and Casual Male Retail Group, Inc. (NASDAQ: CMRG) provides the ...
Cached Medicine News:Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 2Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 3Health News:Driving Danger -- Black Ice Poses Menace on Frigid NY Roadways, New York Attorney Steven J. Schwartzapfel Says 4Health News:Universal Background Screening Expands with Opening of Los Angeles Office 2Health News:Trek Travel Introduces Trek's Ride+ Electric Assist Bikes to Cycling Vacations 2Health News:Mountain Home Experiences a Huge Response to Their Ground Breaking Free Lean Six Sigma Certification Offer 2Health News:Innovative Products Promote Healthy Living and Wellness, 2
... The IMMULITE 1000 immunoassay system features ... reliability, robust hardware and excellent assay ... reagents and accommodates onboard dilutions, positive ... , Worldwide, IMMULITE 1000 (and its ...
... The AIA-1800 is the newest and most ... Inc. The AIA-1800 launches with a full ... markers, thyroid, reproductive, cardiac, and anemia assays. ... throughput, bar-coded primary tube sampling, auto dilution, ...
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... 250 is a flexible system ... multiple environments small hospitals, ... and satellite locations. The Vitros ... and can be automated or ...
Medicine Products: